ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Theranostic π Electron-Stabilized Polymeric Micelles for PET Imaging-Guided Drug Delivery to Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.International journal of nanomedicine · 2026Review
- Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics.Bioactive materials · 2026Review
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- Unlocking tumor barrier: annexin A2-mediated transcytosis boosts drug delivery in pancreatic and breast tumors.Nature communications · 2025Article
- Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review.RSC advances · 2025Review
- Mesoporous polydopamine nanoparticles coated with metal-polyphenol networks for demethylation therapy of lung cancer.Medical oncology (Northwood, London, England) · 2025Article
- Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.ACS applied materials & interfaces · 2025Review
- Gas Vesicle-Assisted Ultrasound Imaging for Effective Anti-Tumour CAR-T Cell Immunotherapy Efficacy in Mice Model.International journal of nanomedicine · 2025Article
- Hemostasis and Gingival Healing-Polyurethane Adhesive Postextraction Under Rivaroxaban Therapy in a Rodent Model.International journal of dentistry · 2025Article
- Assessing Therapeutic Nanoparticle Accumulation in Tumors Using Nanobubble-Based Contrast-Enhanced Ultrasound Imaging.ACS nano · 2024Article
- Histopathological biomarkers for predicting the tumour accumulation of nanomedicines.Nature biomedical engineering · 2024Article
- Advancements in tantalum based nanoparticles for integrated imaging and photothermal therapy in cancer management.RSC advances · 2024Review
- Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Self-supplying CuRSC advances · 2024Article
- Aptamer-Based Smart Targeting and Spatial Trigger-Response Drug-Delivery Systems for Anticancer Therapy.Biomedicines · 2024Review
- Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery.International journal of nanomedicine · 2024Review
- Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches.Drug design, development and therapy · 2024Review
- Repurposing Tamoxifen for Tumor Microenvironment Priming and Enhanced Tumor-Targeted Drug Delivery.Advanced therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 3 countries.
Funding
Abstract
Cancer nanomedicines rely on the enhanced permeability and retention (EPR) effect for efficient target site accumulation. The EPR effect, however, is highly heterogeneous among different tumor types and cancer patients and its extent is expected to dynamically change during the course of nanochemotherapy. Here the authors set out to longitudinally study the dynamics of the EPR effect upon single- and double-dose nanotherapy with fluorophore-labeled and paclitaxel-loaded polymeric micelles. Using computed tomography-fluorescence molecular tomography imaging, it is shown that the extent of nanomedicine tumor accumulation is predictive for therapy outcome. It is also shown that the interindividual heterogeneity in EPR-based tumor accumulation significantly increases during treatment, especially for more efficient double-dose nanotaxane therapy. Furthermore, for double-dose micelle therapy, tumor accumulation significantly increased over time, from 7% injected dose per gram (ID g
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.